Roivant Sciences Shares Rise After Phase 2 Mosliciguat Results

Roivant Sciences (NASDAQ:ROIV) shares rose 22.0% in premarket trading after its Pulmovant subsidiary reported topline results from the Phase 2 PHocus study of mosliciguat in patients with pulmonary hypertension associated with interstitial lung disease, or PH-ILD.

The results were presented at the European Respiratory Society International Congress 2026 by Professor Marc Humbert of Université Paris-Saclay.

PH-ILD is a progressive condition involving pulmonary hypertension in patients with interstitial lung disease. Mosliciguat is an investigational inhaled soluble guanylate cyclase activator being developed as a potential treatment for the condition.

Roivant Begins Phase 3 PHrontier Study

Alongside the Phase 2 announcement, Roivant said the Phase 3 PHrontier study of mosliciguat in PH-ILD has begun and patient enrolment is underway.

The supplied information does not provide detailed efficacy or safety figures from the PHocus study or specify the endpoints achieved. It therefore does not support conclusions about the magnitude of the treatment’s clinical benefit or its prospects for regulatory approval.

Mosliciguat remains an investigational therapy, and its safety and efficacy will require further evaluation through the Phase 3 programme and any subsequent regulatory review.

Roivant also scheduled an investor call and webcast for 8:00 a.m. ET to discuss the Phase 2 findings.

Mosliciguat Adds to Roivant’s Clinical Pipeline

The PHocus results follow another recent development within Roivant’s portfolio.

In late August, subsidiary Priovant received U.S. Food and Drug Administration approval for LISRAYA, or brepocitinib, for dermatomyositis, according to the supplied information.

Roivant operates through subsidiaries developing treatments across several therapeutic areas, including pulmonary and autoimmune diseases.

The company is now advancing mosliciguat through the Phase 3 PHrontier trial while continuing development and commercial activities elsewhere in its portfolio.

Roivant Shares Move Above Previous 52-Week High

Roivant’s 22.0% premarket increase took the shares above their previous 52-week high of $37.97.

The move occurred during a mixed session for broader U.S. equity markets, with the Nasdaq approximately unchanged while the S&P 500 and Dow Jones traded modestly lower.

The Phase 2 PHocus results and initiation of the Phase 3 PHrontier study were the principal company developments identified in the supplied information alongside Tuesday’s premarket share-price movement.

Further information from the Phase 3 study will be required to assess mosliciguat’s efficacy and safety in PH-ILD and its potential path through the regulatory process.

Roivant stock price